HUMAN FAECAL MATTER
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
City of Hope Medical Centerother_biologicalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
23 Active assets in the Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Roswell Park Cancer Institute | Phase 2 | B |
Axicabtagene Ciloleucel City of Hope Medical Center | Phase 2 | B |
Fludarabine Roswell Park Cancer Institute | Phase 2 | B |
cc-5013 David Bond, MD | Phase 2 | B |
Cytosin-Arabinosid University of California, Davis | Phase 2 | B |
View all 26 →
Same molecule, other indications
HUMAN FAECAL MATTER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →